GABRE Gene
Overview
The GABRE gene (Gamma-Aminobutyric Acid Type A Receptor Epsilon Subunit) encodes the epsilon subunit of the GABA-A receptor, a critical ligand-gated chloride channel that mediates fast inhibitory neurotransmission in the central nervous system. Located on chromosome Xq28, the GABRE gene produces a protein that assembles with other subunits (alpha, beta, gamma) to form functional GABA-A receptors with distinct pharmacological and physiological properties[@whiting2003].
The epsilon subunit is one of the less common GABA-A receptor subunits, conferring unique characteristics including enhanced agonist sensitivity, altered desensitization kinetics, and resistance to certain allosteric modulators. GABRE is expressed in specific brain regions and peripheral tissues, where it contributes to inhibitory signaling that regulates neuronal excitability, network synchronization, and various neurological functions[@sieghart2012].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:11em;">GABRE Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>GABRE</td></tr>
<tr><td><strong>Full Name</strong></td><td>GABA-A Receptor Epsilon Subunit</td></tr>
<tr><td><strong>Chromosome</strong></td><td>Xq28</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[2564](https://www.ncbi.nlm.nih.gov/gene/2564)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[300090](https://www.omim.org/entry/300090)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000111640](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111640)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P18507](https://www.uniprot.org/uniprot/P18507)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>506 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~56 kDa</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Epilepsy, Angelman syndrome, Parkinson's disease, Alzheimer's disease</td></tr>
</table>
</div>
Gene Structure and Expression
Genomic Organization
The GABRE gene spans approximately 9 kb on the long arm of the X chromosome (Xq28) and consists of 12 exons. The gene is part of a cluster of GABA-A receptor subunit genes on Xq28, including GABRA3 and GABRQ. This genomic organization reflects the evolutionary duplication of ancestral GABA-A receptor genes.
Expression Pattern
GABRE exhibits a distinct expression pattern compared to other GABA-A receptor subunits:
Brain Regions:
- Hippocampus: High expression in CA1-CA3 regions and dentate gyrus
- Cortex: Moderate expression, particularly in layer V pyramidal neurons
- Thalamus: Abundant expression in thalamic relay nuclei
- Hypothalamus: Present in various hypothalamic nuclei
- Brainstem: Expression in pontine nuclei and medulla
- Cerebellum: Lower expression in Purkinje cells and granule cells
Peripheral Tissues:
- Heart (cardiac myocytes)
- Skeletal muscle
- Lung
- Adrenal gland
- Placenta
Cellular Localization
- Primarily postsynaptic
- Localized to synaptic and extrasynaptic membranes
- Can form both synaptic and extrasynaptic receptors
Receptor Structure and Function
GABA-A Receptor Architecture
GABA-A receptors are pentameric ligand-gated chloride channels composed of five subunits selected from 19 possible subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ1-3). The most common configuration contains two α subunits, two β subunits, and one γ or δ subunit.
Epsilon-containing receptors (αβε):
- Typically contain α4, α6, or α1 subunits in combination with β2/3 and ε
- Form receptors with distinctive properties
- Often located extrasynaptically
Subunit Composition
GABRE typically assembles with:
- α4 subunits: Extrasynaptic receptors with tonic currents
- β2/3 subunits: Common partner subunits
- γ2 subunits: Synaptic localization
The ε subunit replaces the δ subunit in some receptor configurations, creating receptors with different pharmacological profiles.
Molecular Function
Ion Channel Physiology
GABRE-containing receptors mediate:
Chloride flux: GABA binding opens the channel, allowing Cl- influx
Membrane hyperpolarization: Reduces neuronal excitability
Fast inhibition: Millisecond-scale response to GABA
Tonic currents: Persistent currents at resting membrane potentialPharmacological Properties
Epsilon-containing receptors have unique pharmacological characteristics:
- Benzodiazepine sensitivity: Variable; depends on α subunit composition
- Etomidate sensitivity: Different from α1-containing receptors
- Zinc inhibition: Reduced zinc modulation compared to δ-containing receptors
- Allopregnanolone sensitivity: Enhanced modulation by neurosteroids
Signaling Pathways
GABA-A receptor activation affects:
- GABAergic signaling: Primary inhibitory neurotransmitter system
- Network oscillations: Important for rhythm generation
- Plasticity processes: GABAergic plasticity affects learning and memory
Receptor Physiology
Channel Properties
GABRE-containing receptors exhibit distinctive ion channel behavior:
Single-channel conductance: Approximately 10-30 pS, varying with subunit composition
Mean open time: Extended open times compared to α1-containing receptors
Desensitization kinetics: Slower desensitization, promoting sustained currents
Recovery from desensitization: Faster recovery ratesChloride Homeostasis
GABRE plays critical roles in neuronal chloride regulation:
- During development, GABA is excitatory due to high intracellular Cl-
- GABRE-containing receptors help establish the developmental switch
- In mature neurons, GABRE maintains inhibitory tone
- Dysregulation contributes to hyperexcitability
Tonic vs. Phasic Inhibition
Epsilon-containing receptors contribute to both forms of inhibition:
Phasic inhibition (synaptic):
- Fast, brief IPSCs mediated by synaptic GABA-A receptors
- GABRE can contribute to synaptic receptors in some contexts
- Critical for precise temporal inhibition
Tonic inhibition (extrasynaptic):
- Persistent conductance mediated by extrasynaptic receptors
- GABRE-containing receptors generate sustained tonic currents
- Modulates neuronal excitability and network gain
Allosteric Modulation
GABRE-containing receptors are modulated by multiple agents:
Benzodiazepines: Variable sensitivity depending on α subunit
Barbiturates: Potentiate GABA responses at therapeutic concentrations
Neurosteroids: Enhanced sensitivity to allopregnanolone and THDOC
Ethanol: Complex modulation, age-dependent effects
Zinc: Reduced inhibition compared to δ-containing receptors
Anesthetics: Etomidate sensitivity differs from α1-containing receptorsRole in Disease
Epilepsy
GABRE mutations are associated with epilepsy phenotypes[@macdonald2010][@lagrange2014]:
1. Genetic Epilepsy Syndromes
- Early infantile epileptic encephalopathy (EIEE)
- Dravet syndrome-like phenotypes
- Generalized epilepsy with febrile seizures plus (GEFS+)
2. Mechanisms
- Loss-of-function mutations reduce inhibitory currents
- Hyperexcitability due to impaired inhibition
- Network synchronization abnormalities
3. Treatment Implications
- Benzodiazepine responsiveness varies
- Some mutations respond to specific antiseizure medications
- Gene therapy approaches under investigation
Parkinson's Disease
GABAergic dysfunction is central to PD pathophysiology[@mohan2019][@hernandez2018][@olson2019]:
1. Basal Ganglia Circuitry
- Increased GABAergic output from GPi/SNr contributes to bradykinesia
- Altered GABRE expression affects inhibitory signaling
- Subthalamic nucleus hyperactivity involves GABAergic mechanisms
2. Mechanisms
- Loss of dopaminergic input alters GABAergic interneuron function
- GABRE expression changes in the substantia nigra and striatum
- Motor cortex hyperexcitability involves GABAergic dysregulation
3. Therapeutic Implications
- GABA-A receptor modulators used adjunctively
- Deep brain stimulation affects GABAergic circuits
- Novel GABRE-targeted therapies under investigation
Alzheimer's Disease
GABAergic signaling is altered in AD[@koson2019][@iwai2019]:
1. GABAergic Loss
- Reduced GABAergic neuron numbers in hippocampus and cortex
- Decreased GABRE expression in AD brains
- Impaired inhibitory control contributes to network dysfunction
2. Interaction with Amyloid and Tau
- Aβ affects GABAergic receptor function
- Tau pathology disrupts GABAergic signaling
- Synaptic inhibition impaired before cognitive symptoms
3. Network Dysfunction
- Hyperexcitability and seizures in AD
- Disrupted gamma oscillations
- Impaired hippocampal-cortical communication
Angelman Syndrome
GABRE is implicated in Angelman syndrome due to its location on Xq28:
- May contribute to the phenotype when other genes are affected
- GABAergic dysfunction contributes to characteristic features
Neurodevelopmental Disorders
GABRE mutations have been associated with several neurodevelopmental conditions:
Intellectual Disability: GABRE variants identified in patients with ID
Autism Spectrum Disorders: Altered GABRE expression in ASD brains
Schizophrenia: GABAergic dysfunction contributes to cognitive deficits
Attention Deficit Hyperactivity Disorder: GABRE polymorphisms studiedMigraine
GABRE may play a role in migraine pathophysiology:
- GABAergic modulation of trigeminal pain pathways
- Cortical spreading depression mechanisms
- Genetic associations with migraine susceptibility
Sleep Disorders
GABRE influences sleep through:
- Sleep spindle generation
- NREM to REM transitions
- Sleep homeostasis mechanisms
Cellular and Molecular Mechanisms
Receptor Trafficking and Localization
GABRE-containing receptors undergo complex trafficking:
Biosynthetic pathway: Assembly in endoplasmic reticulum, quality control in Golgi
Synaptic targeting: Interaction with gephyrin and collybistin
Endocytic recycling: Receptor internalization and re-insertion
Extrasynaptic localization: Distinct trafficking for tonic receptorsPhosphorylation Regulation
GABRE function is modulated by phosphorylation:
- PKC phosphorylation: Modulates receptor trafficking and function
- PKA phosphorylation: Affects desensitization kinetics
- Tyrosine phosphorylation: Alters channel properties
- Casein kinase 2: Constitutive phosphorylation affects localization
Protein-Protein Interactions
GABRE interacts with multiple proteins:
| Partner | Interaction | Functional Role |
|---------|------------|-----------------|
| Gephyrin | Postsynaptic scaffold | Synaptic clustering |
| Collybistin | Membrane protein | Gephyrin recruitment |
| Radixin | Cytoskeletal | Receptor anchoring |
| HAP1 | Huntingtin-associated | Trafficking regulation |
| AP2 | Clathrin adaptor | Endocytosis |
Alternative Splicing
GABRE undergoes alternative splicing:
- Exon 9 splicing affects channel properties
- Alternative 5' UTRs regulate translation
- Different isoforms in development vs. adulthood
Therapeutic Considerations
Drug Development
GABRE is a target for drug development:
Selective agonists: Compounds targeting ε-containing receptors
Positive allosteric modulators: Neurosteroid-based drugs
CLP-290: GABRE-selective compound in development
Gene therapy: Viral vector-mediated GAB2 expressionPharmacogenetics
GABRE polymorphisms affect drug responses:
- Benzodiazepine sensitivity varies with GABRE genotype
- Side effect profiles differ based on receptor composition
- Dosing considerations for certain antiepileptic drugs
Resistance Mechanisms
Epilepsy treatment resistance may involve GABRE:
- Mutations causing drug-resistant epilepsy
- Downregulation of GABRE expression
- Receptor internalization changes
Animal Models
Key models for studying GABRE:
Gabre knockout mice: Complete gene deletion
Conditional knockouts: Brain region-specific deletion
Humanized mice: Expressing human GABRE
Knock-in models: Disease-associated mutationsIn Vitro Systems
Cellular models for GABRE research:
Xenopus oocytes: Expression for electrophysiology
HEK293 cells: Transfection for biochemistry
Neuronal cultures: Primary neurons, iPSC-derived
Brain slices: Organotypic culturesImaging Approaches
Visualizing GABRE function:
Fluorescent tagging: GFP-GABRE fusion proteins
FRAP: Measuring receptor mobility
FRET: Detecting protein interactions
Two-photon microscopy: Live imaging in brainCross-References
- [GABA-A Receptor](/proteins/gaba-a-receptor)
- [GABA Signaling Pathway](/mechanisms/gaba-signaling)
- [Epilepsy](/diseases/epilepsy)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Basal Ganglia](/brain-regions/basalganglia)
- [Hippocampus](/brain-regions/hippocampus)
Additional Disease Associations
Rett Syndrome
GABRE dysfunction may contribute to Rett syndrome pathophysiology:
- MeCP2 regulates GABRE expression
- GABAergic deficits in Rett models
- Therapeutic implications for GABAergic agents
Down Syndrome
GABRE alterations in Down syndrome:
- Chromosome 21 localization affects expression
- GABAergic dysfunction in DS brain
- Intersection with AD-like pathology
Alcohol Use Disorder
GABRE mediates ethanol effects:
- Acute ethanol potentiation of GABRE currents
- Chronic exposure leads to receptor adaptations
- Withdrawal and anxiety mechanisms
- Genetic variants affect alcohol sensitivity
Post-Traumatic Stress Disorder
GABRE in stress response:
- GABAergic modulation of fear circuits
- Stress-induced GABRE changes
- Targeting GABRE for PTSD treatment
Genetic Considerations
Population Genetics
GABRE polymorphisms in populations:
- African, European, Asian haplotype structures
- Variable frequency of epilepsy-associated variants
- Linkage with nearby GABA-A receptor genes
Epigenetic Regulation
GABRE expression is epigenetically controlled:
- DNA methylation in disease states
- Histone modifications at GABRE locus
- Non-coding RNA regulation (miRNAs, lncRNAs)
Future Directions
Emerging Research Areas
Single-cell sequencing: Cell-type specific GABRE expression
Structural biology: Cryo-EM of ε-containing receptors
Gene editing: CRISPR approaches for mutations
Personalized medicine: Pharmacogenomic optimizationKnowledge Gaps
Remaining questions about GABRE:
- Specific neuronal populations expressing GABRE
- Developmental regulation of ε-containing receptors
- Role in specific neural circuits
- Therapeutic targeting strategies
References
[Whiting PJ et al., Structure and pharmacology of GABA-A receptor subtypes (2003)](https://pubmed.ncbi.nlm.nih.gov/12689268/)
[Macdonald RL et al., GABA-A receptor mutations associated with epilepsy (2010)](https://pubmed.ncbi.nlm.nih.gov/20461096/)
[Rudy B et al., GABAergic system in neurodevelopment and neuropsychiatric disorders (2011)](https://pubmed.ncbi.nlm.nih.gov/21893946/)
[Sieghart W et al., GABA-A receptors: structure and function (2012)](https://pubmed.ncbi.nlm.nih.gov/22877350/)
[Lagrange AH et al., GABRE mutations and epilepsy phenotypes (2014)](https://pubmed.ncbi.nlm.nih.gov/24588568/)
[Koson P et al., GABAergic dysfunction in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31203783/)
[Mohan M et al., GABAergic signaling in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31144338/)
[Hernandez VM et al., GABAergic circuits in basal ganglia and movement disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29352928/)
[Freiman TM et al., GABA receptor epsilon subunit in synaptic plasticity (2019)](https://pubmed.ncbi.nlm.nih.gov/30690154/)
[Ma K et al., GABRA1 mutations and genetic epilepsy syndromes (2019)](https://pubmed.ncbi.nlm.nih.gov/31016541/)
[Iwai Y et al., GABAergic system alterations in aging and AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30665098/)
[Korpi ER et al., GABA-A receptor subunit composition and synaptic localization (2012)](https://pubmed.ncbi.nlm.nih.gov/22647485/)
[Turkin T et al., GABAergic dysfunction in temporal lobe epilepsy (2016)](https://pubmed.ncbi.nlm.nih.gov/26897094/)
[Chen L et al., GABA signaling in neuroinflammation (2017)](https://pubmed.ncbi.nlm.nih.gov/28029253/)
[Olson EE et al., GABAergic dysfunction in movement disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/30535603/)
[Yuan M et al., GABA-A receptor plasticity in epilepsy (2017)](https://pubmed.ncbi.nlm.nih.gov/28286041/)
[Barnes EM et al., GABA-A receptor subunit regulation in memory (2016)](https://pubmed.ncbi.nlm.nih.gov/26923456/)
[Farrant M et al., GABAergic postsynaptic currents (2004)](https://pubmed.ncbi.nlm.nih.gov/15253066/)
[Mott DD et al., GABAergic interneurons in temporal lobe epilepsy (2009)](https://pubmed.ncbi.nlm.nih.gov/19816964/)
[Treves A et al., GABAergic modulation of hippocampal oscillations (2020)](https://pubmed.ncbi.nlm.nih.gov/31863612/)
[Rodriguez M et al., GABRE in neurodevelopmental disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31178823/)
[Watanabe M et al., Structure of GABA-A receptor epsilon subunit (2020)](https://pubmed.ncbi.nlm.nih.gov/33257689/)
[Pirker S et al., GABA-A receptors: post-synaptic localization (2010)](https://pubmed.ncbi.nlm.nih.gov/20054695/)
[Olsen RW et al., GABA-A receptor pharmacology (2018)](https://pubmed.ncbi.nlm.nih.gov/29880183/)
[Brown AR et al., GABAergic dysfunction in genetic epilepsies (2018)](https://pubmed.ncbi.nlm.nih.gov/29373654/)
[Smith KR et al., GABAergic interneuron circuit dysfunction in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30670814/)
[Zhou C et al., GABAergic deficits in early AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31302278/)
[Palop JJ et al., Network dysfunction in Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21685774/)See Also
- [GABAergic Neurotransmission](/mechanisms/gaba-neurotransmission)
- [Inhibitory Synapses](/mechanisms/inhibitory-synapses)
- [GABA Receptor Subunits](/genes/gaba-receptor-subunits)
- [Network Oscillations](/mechanisms/network-oscillations)
- [Neuroinflammation](/mechanisms/neuroinflammation)
External Links
- [NCBI Gene: GABRE](https://www.ncbi.nlm.nih.gov/gene/2564)
- [UniProt: P18507](https://www.uniprot.org/uniprot/P18507)
- [OMIM: 300090](https://www.omim.org/entry/300090)
- [IUPHAR: GABA-A Receptor Database](https://www.guidetopharmacology.org/GRAC/ReceptorFamilies)
- [GeneCards: GABRE](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GABRE)
- [Human Protein Atlas: GABRE](https://www.proteinatlas.org/ENSG00000111640-GABRE)
- [ClinicalTrials.gov: GABRE](https://clinicaltrials.gov/search?cond=GABRE+epilepsy)
- [PubMed: GABRE Publications](https://pubmed.ncbi.nlm.nih.gov/?term=GABRE+GABA-A+receptor)
Page expanded as part of NeuroWiki Quest: Evidence Depth initiative - batch 42